Fully humanized antibody that is used in the treatment of rheumatoid arthritis is–

Ref:   Katzung’s ‘Basic and Clinical Pharmacology’; 9/e,pg592 Adalimumab: Adalimumabisarecombinanthumananti-TNFmonoclonalantibody. This compound complexes with soluble TNF-α and prevents its interaction with p55 and p75 cell surface receptors. This results in down-regulation of macrophage and T-cell function. Option (a): Etanercept– Ref: Katzung’s ‘Basic and Clinical Pharmacology’; 9/e, pg 593 Etanerceptis are combin ant fusion protein consisting of two soluble TNF p75 receptor moieties linked to the Fc portion of human IgG1. It binds TNF-α molecules and also inhibits lymphotoxin-α. Option (c): Infliximab– Ref: Katzung’s ‘Basic and Clinical Pharmacology’; 9/e, pg 592 Infliximab is a chimeric (25% mouse, 75% human) monoclonal antibody that binds with high affinity to  soluble and poorly membrane-bound TNF-α. Its mechanism of action is probably the same as that of adalimumab. Option (b): Anakinra– Ref: K.D.Tripathi’s ‘Essentials of Medical Pharamacology’; 6/e, pg 205. It is a recombinant human IL-1 receptorantagonist. Though clinically less effective than TNF-α inhibitors, it has been used in cases who have failed on one or  more DMARDs. Dose: 100 mg s.c.daily.